Merseyside Inter Agency Drug Misuse Database

January - March 2010

Wirral DAAT

Quarter 4 2009/10

Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:
The Authors would like to thank the following for their valuable contributions to the production of this report: Ellie McCoy and Paul Duffy.
We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
4th Floor, Kingsway House
Hatton Gardens
Liverpool
L3 2AY

(0151) 904 6031
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 8014
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

Page

Introduction 1

Arrest Referral 3

Table 1: Individuals assessed, by Gender and Age Group
Table 2: Year to Date, by Gender and Age Group
Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Needle and Syringe Programmes (NSPs) 5

Agency

Table 4: Individuals by Gender
Table 5: Individuals by Gender: Steroid Users omitted
Table 6: Individuals by Age Group
Table 7: Individuals by Age Group: Steroid Users omitted
Table 8: Gender by Age Group of Individuals
Table 9: Gender by Age Group: Steroid Users omitted
Table 10: Year to Date, by Gender & Age Group
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted
Table 12: Main Drug of Use for New Agency NSP Clients, by Gender
Table 13: Main Drug of Use for All Agency NSP Clients, by Gender
Table 14: Main Drug of Use, for New Agency NSP Clients, by Age Group

Pharmacy 11

Table 15: Individuals by Gender
Table 16: Individuals by Age Group
Table 17: Year to Date, by Gender & Age Group

Combined 12

Table 18: Individuals in NSP, by Gender
Table 19: Individuals in NSP, by Gender: Steroid Users omitted
Table 20: Individuals in NSP, by Age Group
Table 21: Individuals in NSP, by Age Group: Steroid Users omitted
Table 22: Year to Date, by Gender & Age Group
Table 23: Total Syringes Provided

National Drug Treatment Monitoring System (NDTMS) **14**

Table 24: Individuals in contact with Treatment Services, by Gender
Table 25: Year to Date, by Gender
Table 26: Individuals in contact with Treatment Services, by Age Group
Table 27: Year to Date, by Age Group
Table 28: Ethnicity of Individuals in Contact with Treatment Services
Table 29: Individuals in contact with Treatment Services, by Main Drug of Use

Connexions **17**

Table 30: Individuals in Contact with Connexions, by Gender
Table 31: Year to Date, by Gender
Table 32: Individuals in Contact with Connexions, by Age
Table 33: Year to Date, by Age
Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem
Table 35: Year to Date, by Drug/Alcohol Problem

Combined Datasets **19**

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group
Table 37: Year to Date, by Gender & Age Group

Cross Matched Datasets **20**

Fig 1: Crossover between Agency NSP and NDTMS datasets
Fig 2: Crossover between Pharmacy NSP and NDTMS datasets
Fig 3: Crossover between YTD Agency NSP and NDTMS datasets
Fig 4: Crossover between YTD Pharmacy NSP and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2009/10)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	112	80.0
Female	28	20.0
Age Group		
Under 18	0	0.0
18-19	8	5.7
20-24	27	19.3
25-29	20	14.3
30-34	23	16.4
35-39	18	12.9
40-44	23	16.4
45+	21	15.0
Total	140	100

Table 2: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	0	0.0	0	0.0	0	0.0
18-19	22	4.7	5	5.2	27	4.8
20-24	87	18.7	16	16.7	103	18.3
25-29	97	20.8	12	12.5	109	19.4
30-34	72	15.5	16	16.7	88	15.7
35-39	70	15.0	15	15.6	85	15.1
40-44	64	13.7	15	15.6	79	14.1
45+	54	11.6	17	17.7	71	12.6
Total	466	100	96	100	562	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	0	0	2
Benzodiazepines	0	0	1
Cannabis	14	5	1
Crack	6	1	1
Cocaine	4	15	29
Ecstasy	-	-	-
Heroin	30	13	8
Methadone	2	0	0
Other	-	-	-

14 individuals did not report a main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2009/10)

Introduction

Data are collected directly from NSP providers. Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	143	96.6
Female	5	3.4
Total	148	100
All Clients		
Male	589	96.1
Female	24	3.9
Total	613	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	41	89.1
Female	5	10.9
Total	46	100
All Clients		
Male	183	88.8
Female	23	11.2
Total	206	100

Table 6: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	**%**	n	**%**
Under 18	2	1.4	3	<1
18-19	13	8.8	29	4.7
20-24	40	27.0	133	21.7
25-29	25	16.9	98	16.0
30-34	27	18.2	107	17.5
35-39	18	12.2	98	16.0
40-44	12	8.1	79	12.9
45+	11	7.4	66	10.8
Total	148	100	613	100

Table 7: Individuals by Age Group: Steroid Users omitted

	New Clients		All Clients	
Age Group	n	**%**	n	**%**
Under 18	1	2.2	1	<1
18-19	0	0.0	0	0.0
20-24	1	2.2	3	1.5
25-29	6	13.0	18	8.7
30-34	11	23.9	39	18.9
35-39	13	28.3	55	26.7
40-44	7	15.2	49	23.8
45+	7	15.2	41	19.9
Total	46	100	206	100

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	3	<1	0	0.0
18-19	29	4.9	0	0.0
20-24	133	22.6	0	0.0
25-29	95	16.1	3	12.5
30-34	100	17.0	7	29.2
35-39	90	15.3	8	33.3
40-44	75	12.7	4	16.7
45+	64	10.9	2	8.3
Total	589	100	24	100

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	2	<1	0	0.0
18-19	0	0.0	0	0.0
20-24	3	1.6	0	0.0
25-29	15	8.2	3	13.0
30-34	32	17.5	7	30.4
35-39	47	25.7	8	34.8
40-44	45	24.6	4	17.4
45+	40	21.9	1	4.3
Total	183	100	23	100

Table 10: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	11	<1	1	1.7	12	<1
18-19	73	5.3	1	1.7	74	5.2
20-24	321	23.4	3	5.0	324	22.7
25-29	238	17.4	9	15.0	247	17.3
30-34	236	17.2	14	23.3	250	17.5
35-39	213	15.5	18	30.0	231	16.2
40-44	161	11.8	9	15.0	170	11.9
45+	117	8.5	5	8.3	122	8.5
Total	1,370	100	60	100	1,430	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	3	<1	1	1.8	4	<1
18-19	2	<1	0	0.0	2	<1
20-24	28	5.9	3	5.3	31	5.8
25-29	41	8.6	9	15.8	50	9.4
30-34	86	18.1	13	22.8	99	18.6
35-39	133	28.0	18	31.6	151	28.4
40-44	103	21.7	9	15.8	112	21.1
45+	79	16.6	4	7.0	83	15.6
Total	475	100	57	100	532	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Amphetamines	1	<1	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	<1	0	0.0
Crack	0	0.0	0	0.0
Heroin	23	16.1	4	80.0
Methadone	4	2.8	0	0.0
Steroids	102	71.3	0	0.0
Various	1	<1	0	0.0
Unknown	7	4.9	0	0.0
Other	4	2.8	1	20.0
Total	143	100	5	100

Table 13: Main Drug of Use for All Agency NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Amphetamines	5	<1	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	2	<1	0	0.0
Crack	0	0.0	0	0.0
Heroin	126	21.4	17	70.8
Methadone	20	3.4	3	12.5
Various	3	<1	0	0.0
Steroids	406	68.9	1	4.2
Other	6	1.9	1	4.2
Unknown	21	3.6	2	8.4
Total	589	100	24	100

Current Quarter; Melanotan Clients

- 0 New Male clients reported using melanotan during Q4
- 2 New Female clients reported using melanotan during Q4
- 1 Male clients reported using melanotan during Q4
- 2 Female clients reported using melanotan during Q4

Table 14: Main Drug of Use for New Agency NSP Clients, by Age Group

	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
Age Group	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Under 18	0	0.0	-	-	0	0.0	-	-	0	0.0	0	0.0	1	1.0
18-19	0	0.0	-	-	0	0.0	-	-	0	0.0	0	0.0	13	12.7
20-24	0	0.0	-	-	0	0.0	-	-	1	3.7	0	0.0	39	38.2
25-29	0	0.0	-	-	0	0.0	-	-	1	3.7	0	0.0	19	18.6
30-34	0	0.0	-	-	1	100	-	-	5	18.5	1	25.0	16	15.7
35-39	1	100	-	-	0	0.0	-	-	9	33.3	0	0.0	5	4.9
40-44	0	0.0	-	-	0	0.0	-	-	6	22.2	1	25.0	5	4.9
45+	0	0.0	-	-	0	0.0	-	-	5	18.5	2	50.0	4	3.9
Total	1	100	-	-	1	100	-	-	27	100	4	100	102	100

% Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY NSP

There was a disruption to pharmacy NSP data submission during 2009/10 resulting in a loss of data. This data has since been submitted and is reflected in the year to date figures provided in this report. For further details please contact the IAD.

Table 15: Individuals by Gender

New Clients	n	%
Male	11	91.7
Female	1	8.3
Total	12	100
All Clients		
Male	105	81.4
Female	24	18.6
Total	129	100

Table 16: Individuals by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	1	8.3	5	3.9
25-29	1	8.3	8	6.2
30-34	3	25.0	19	14.7
35-39	4	33.3	39	30.2
40-44	2	16.7	24	18.6
45+	1	8.3	34	26.4
Total	12	100	129	100

Table 17: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	0	0.0	0	0.0	0	0.0
18-19	5	1.7	0	0.0	5	1.5
20-24	19	6.6	3	5.7	22	6.5
25-29	29	10.1	6	11.3	35	10.3
30-34	43	15.0	8	15.1	51	15.0
35-39	73	25.4	16	30.2	89	26.2
40-44	58	20.2	9	17.0	67	19.7
45+	60	20.9	11	20.8	71	20.9
Total	287	100	53	100	340	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 18: Individuals in NSP, by Gender

New Clients	n	%
Male	154	96.3
Female	6	3.8
Total	160	100
All Clients		
Male	673	94.4
Female	40	5.6
Total	713	100

Table 19: Individuals in NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	52	89.7
Female	6	10.3
Total	58	100
All Clients		
Male	267	87.3
Female	39	12.7
Total	306	100

*Only known steroid users, based on Agency NSP data, have been omitted.

Table 20: Individuals in NSP, by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	2	1.3	3	<1
18-19	13	8.1	29	4.1
20-24	41	25.6	138	19.4
25-29	26	16.3	102	14.3
30-34	30	18.8	117	16.4
35-39	22	13.8	129	18.1
40-44	14	8.8	99	13.9
45+	12	7.5	96	13.5
Total	160	100	713	100

Table 21: Individuals in NSP by Age Group: Steroid Users Omitted

	New Clients		All Clients	
Age Group	n	**%**	n	**%**
Under 18	1	1.7	1	<1
18-19	0	0.0	0	0.0
20-24	2	3.4	8	2.6
25-29	7	12.1	22	7.2
30-34	14	24.1	49	16.0
35-39	17	29.3	86	28.1
40-44	9	15.5	69	22.5
45+	8	13.8	71	23.2
Total	58	100	306	100

Table 22: Year to Date, by Gender & Age Group

	Gender					
	Male		**Female**		***Total in Age Group***	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	11	<1	1	1.0	12	<1
18-19	78	5.0	1	1.0	79	4.8
20-24	332	21.2	5	5.2	337	20.3
25-29	261	16.7	11	11.5	272	16.4
30-34	262	16.7	20	20.8	282	17.0
35-39	261	16.7	28	29.2	289	17.4
40-44	199	12.7	16	16.7	215	12.9
45+	163	10.4	14	14.6	177	10.6
Total	1,567	100	96	100	1,663	100

Table 23: Total Syringes Provided

	Agency	**Pharmacy**	**Total (Q)**	**Year to Date**
Barrels	31,640	6,920	38,560	156,862

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2009/10)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 24: Individuals in Contact with Treatment Services, by Gender

New Clients	n	**%**
Male	212	76.5
Female	65	23.5
Total	277	100
All Clients		
Male	2,063	73.1
Female	759	26.9
Total	2,822	100

Table 25: Year to Date, by Gender

New Clients	n	**%**
Male	688	75.6
Female	222	24.4
Total	910	100
All Clients		
Male	2,094	72.8
Female	783	27.2
Total	2,877	100

Table 26: Individuals in Contact with Treatment Services, by Age Group

	New Clients		All Clients	
Age Group	n	**%**	n	**%**
Under 18	21	7.6	131	4.6
18-19	7	2.5	55	1.9
20-24	26	9.4	246	8.7
25-29	29	10.5	449	15.9
30-34	48	17.3	566	20.1
35-39	60	21.7	664	23.5
40-44	51	18.4	446	15.8
45+	35	12.6	265	9.4
Total	277	100	2,822	100

Table 27: Year to Date, by Age Group

	New Clients		All Clients	
Age Group	n	**%**	n	**%**
Under 18	82	9.0	134	4.7
18-19	24	2.6	55	1.9
20-24	78	8.6	254	8.8
25-29	113	12.4	469	16.3
30-34	157	17.3	579	20.1
35-39	175	19.2	677	23.5
40-44	165	18.1	451	15.7
45+	116	12.7	258	9.0
Total	910	100	2,877	100

Table 28: Ethnicity of Individuals in Contact with Treatment Services

	New Clients		All Clients	
Ethnicity	**n**	**%**	**n**	**%**
White British	267	96.4	2,760	97.8
White Irish	3	1.1	14	<1
Other White	3	1.1	7	<1
White & Black Caribbean	1	<1	11	<1
White & Black African	0	0.0	0	0.0
African	1	0.0	2	<1
White & Asian	0	0.0	5	<1
Other Black	0	0.0	4	<1
Other Asian	0	0.0	3	<1
Other Mixed	1	0.0	5	<1
Caribbean	0	0.0	1	<1
Chinese	0	0.0	0	0.0
Other	0	0.0	1	<1
Unknown	1	<1	9	<1
Total	277	100	2,822	100

Table 29: Individuals in Contact with Treatment Services, by Main Drug of Use

	New Clients		All Clients	
Drug of Use	**n**	**%**	**n**	**%**
Heroin	128	46.2	1,921	68.1
Methadone	44	15.9	248	8.8
Other Opiates	15	5.4	47	1.7
Benzodiazepine	3	1.1	9	<1
Amphetamines	6	2.2	52	1.8
Cocaine	32	11.6	211	7.5
Crack	7	2.5	71	2.5
Ecstasy	0	0.0	3	<1
Cannabis	38	13.7	212	7.5
Prescription Drugs	0	0.0	42	1.5
Hallucinogens	1	< 2	3	<1
Other/Unknown	3	1.2	3	<1
Total	*277*	*100*	*2,822*	*100*

CONNEXIONS

Quarter 4 (2009/10)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 30: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	114	73.5
Female	41	26.5
Total	155	100

Table 31: Year to Date, by Gender

Gender	n	%
Male	168	70.3
Female	71	29.7
Total	239	100

Table 32: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	39	25.2
17	38	24.5
18	43	27.7
19	35	22.6
Total	155	100

Table 33: Year to Date, by Age

Age Group	n	%
16	55	23.0
17	48	20.1
18	68	28.5
19	68	28.5
Total	239	100

Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	61	39.4
Drugs	94	60.6
Total	155	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 35: Year to Date, by Drug/Alcohol problem

Substance	n	%
Alcohol/Other*	100	41.8
Drugs	139	58.2
Total	239	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS

Quarter 4 (2009/10)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSP (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	**%**
Male	2,707	76.7
Female	821	23.3
Age Group		
Under 18	195	5.5
18-19	157	4.5
20-24	399	11.3
25-29	544	15.4
30-34	662	18.8
35-39	745	21.1
40-44	511	14.5
45+	315	8.9
Total	3,528	100

Table 37: Year to Date, by Gender and Age Group

	Gender					
	Male		**Female**		***Total in Age Group***	
Age Group	**n**	**%**	**n**	**%**	***n***	***%***
Under 18	177	4.7	54	5.8	231	4.9
18-19	206	5.5	65	6.9	271	5.8
20-24	549	14.7	104	11.1	653	14.0
25-29	601	16.1	158	16.8	759	16.2
30-34	664	17.7	184	19.6	848	18.1
35-39	716	19.1	184	19.6	900	19.2
40-44	502	13.4	115	12.3	617	13.2
45+	326	8.7	74	7.9	400	8.5
Total	3,741	100	938	100	4,679	100

CROSS-MATCHED DATASETS

Quarter 4 (2009/10)

Data are shown for the crossover between each type of NSP and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of NSP site.

Fig 1: Crossover between Agency NSP and NDTMS datasets



Fig 2: Crossover between Pharmacy NSP and NDTMS datasets



Fig 3: Year to Date Crossover between Agency NSP and NDTMS datasets



Fig 4: Year to Date Crossover between Pharmacy NSP and NDTMS datasets